Skip to main content
Top
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database

Authors: Jialun Zhou, Thira Sirisanthana, Sasisopin Kiertiburanakul, Yi-Ming A Chen, Ning Han, Poh_Lian Lim, Nagalingeswaran Kumarasamy, Jun Yong Choi, Tuti Parwati Merati, Evy Yunihastuti, Shinichi Oka, Adeeba Kamarulzaman, Praphan Phanuphak, Christopher KC Lee, Patrick CK Li, Sanjay Pujari, Vanthanak Saphonn, Matthew G Law

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

The aim of this study was to examine the relationship between trends in CD4 counts (slope) and HIV viral load (VL) after initiation of combination antiretroviral treatment (cART) in Asian patients in The TREAT Asia HIV Observational Database (TAHOD).

Methods

Treatment-naive HIV-infected patients who started cART with three or more and had three or more CD4 count and HIV VL tests were included. CD4 count slopes were expressed as changes of cells per microliter per year. Predictors of CD4 count slopes from 6 months after initiation were assessed by random-effects linear regression models.

Results

A total of 1676 patients (74% male) were included. The median time on cART was 4.2 years (IQR 2.5-5.8 years). In the final model, CD4 count slope was associated with age, concurrent HIV VL and CD4 count, disease stage, hepatitis B or C co-infection, and time since cART initiation. CD4 count continues to increase with HIV VL up to 20 000 copies/mL during 6-12 months after cART initiation. However, the HIV VL has to be controlled below 5 000, 4 000 and 500 copies/mL for the CD4 count slope to remain above 20 cells/microliter per year during 12-18, 18-24, and beyond 24 months after cART initiation.

Conclusions

After cART initiation, CD4 counts continued to increase even when the concurrent HIV VL was detectable. However, HIV VL needed to be controlled at a lower level to maintain a positive CD4 count slope when cART continues. The effect on long-term outcomes through the possible development of HIV drug resistance remains uncertain.
Appendix
Available only for authorised users
Literature
1.
go back to reference Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999, 5 (5): 512-517. 10.1038/8394.CrossRefPubMed Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999, 5 (5): 512-517. 10.1038/8394.CrossRefPubMed
3.
go back to reference WHO, UNAIDS, UNICEF: Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. Geneva. 2009 WHO, UNAIDS, UNICEF: Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. Geneva. 2009
4.
go back to reference Hogan DR, Salomon JA: Prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome in resource-limited settings. Bull World Health Organ. 2005, 83 (2): 135-143.PubMedPubMedCentral Hogan DR, Salomon JA: Prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome in resource-limited settings. Bull World Health Organ. 2005, 83 (2): 135-143.PubMedPubMedCentral
5.
go back to reference Boyd MA, Cooper DA: Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS. 2007, 21 (Suppl 4): S55-63. 10.1097/01.aids.0000279707.01557.b2.CrossRefPubMed Boyd MA, Cooper DA: Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS. 2007, 21 (Suppl 4): S55-63. 10.1097/01.aids.0000279707.01557.b2.CrossRefPubMed
6.
go back to reference Zhou J, Li P, Kumarasamy N, Boyd M, Chen Y, Sirisanthana T, Sungkanuparph S, Oka S, Tau G, Phanuphak P, Saphonn V, Zhang F, Omar S, Lee C, Ditangco R, Merati T, Lim P, Choi J, Law M, Pujari S: Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD). HIV Med. 2009, 11 (1): 31-39.PubMedPubMedCentral Zhou J, Li P, Kumarasamy N, Boyd M, Chen Y, Sirisanthana T, Sungkanuparph S, Oka S, Tau G, Phanuphak P, Saphonn V, Zhang F, Omar S, Lee C, Ditangco R, Merati T, Lim P, Choi J, Law M, Pujari S: Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD). HIV Med. 2009, 11 (1): 31-39.PubMedPubMedCentral
7.
go back to reference Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN: Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004, 364 (9428): 51-62. 10.1016/S0140-6736(04)16589-6.CrossRefPubMed Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN: Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004, 364 (9428): 51-62. 10.1016/S0140-6736(04)16589-6.CrossRefPubMed
8.
go back to reference Mocroft A, Phillips AN, Ledergerber B, Smith C, Bogner JR, Lacombe K, Wiercinska-Drapalo A, Reiss P, Kirk O, Lundgren JD: Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Antivir Ther. 2010, 15 (4): 563-570. 10.3851/IMP1559.CrossRefPubMed Mocroft A, Phillips AN, Ledergerber B, Smith C, Bogner JR, Lacombe K, Wiercinska-Drapalo A, Reiss P, Kirk O, Lundgren JD: Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Antivir Ther. 2010, 15 (4): 563-570. 10.3851/IMP1559.CrossRefPubMed
9.
go back to reference Boyd M, Emery S, Cooper DA: Antiretroviral roll-out: the problem of second-line therapy. Lancet. 2009, 374 (9685): 185-186. 10.1016/S0140-6736(09)61313-1.CrossRefPubMed Boyd M, Emery S, Cooper DA: Antiretroviral roll-out: the problem of second-line therapy. Lancet. 2009, 374 (9685): 185-186. 10.1016/S0140-6736(09)61313-1.CrossRefPubMed
10.
go back to reference Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee CK, Li PC, Paton NI, Phanuphak P, Pujari S, Vibhagool A, Wong WW, Zhang F, Chuah J, Frost KR, Cooper DA, Law MG: The TREAT Asia HIV Observational Database: Baseline and Retrospective Data. J Acquir Immune Defic Syndr. 2005, 38 (2): 174-179. 10.1097/01.qai.0000145351.96815.d5.CrossRefPubMedPubMedCentral Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee CK, Li PC, Paton NI, Phanuphak P, Pujari S, Vibhagool A, Wong WW, Zhang F, Chuah J, Frost KR, Cooper DA, Law MG: The TREAT Asia HIV Observational Database: Baseline and Retrospective Data. J Acquir Immune Defic Syndr. 2005, 38 (2): 174-179. 10.1097/01.qai.0000145351.96815.d5.CrossRefPubMedPubMedCentral
11.
go back to reference Kaufmann GR, Zaunders JJ, Cunningham P, Kelleher AD, Grey P, Smith D, Carr A, Cooper DA: Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS. 2000, 14 (17): 2643-2651. 10.1097/00002030-200012010-00003.CrossRefPubMed Kaufmann GR, Zaunders JJ, Cunningham P, Kelleher AD, Grey P, Smith D, Carr A, Cooper DA: Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS. 2000, 14 (17): 2643-2651. 10.1097/00002030-200012010-00003.CrossRefPubMed
12.
go back to reference Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M: CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003, 163 (18): 2187-2195. 10.1001/archinte.163.18.2187.CrossRefPubMed Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M: CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003, 163 (18): 2187-2195. 10.1001/archinte.163.18.2187.CrossRefPubMed
13.
go back to reference Moore RD, Keruly JC: CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007, 44 (3): 441-446. 10.1086/510746.CrossRefPubMed Moore RD, Keruly JC: CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007, 44 (3): 441-446. 10.1086/510746.CrossRefPubMed
14.
go back to reference Egger S, Petoumenos K, Kamarulzaman A, Hoy J, Sungkanuparph S, Chuah J, Falster K, Zhou J, Law MG: Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr. 2009, 50 (5): 513-520. 10.1097/QAI.0b013e31819906d3.CrossRefPubMedPubMedCentral Egger S, Petoumenos K, Kamarulzaman A, Hoy J, Sungkanuparph S, Chuah J, Falster K, Zhou J, Law MG: Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr. 2009, 50 (5): 513-520. 10.1097/QAI.0b013e31819906d3.CrossRefPubMedPubMedCentral
15.
go back to reference Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, Vetter N, Bruun JN, Johnson M, Lundgren JD: Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 2001, 183 (8): 1290-1294. 10.1086/319678.CrossRefPubMed Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, Vetter N, Bruun JN, Johnson M, Lundgren JD: Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 2001, 183 (8): 1290-1294. 10.1086/319678.CrossRefPubMed
16.
go back to reference Parsons JT, Golub SA, Rosof E, Holder C: Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial. J Acquir Immune Defic Syndr. 2007, 46 (4): 443-450. 10.1097/QAI.0b013e318158a461.CrossRefPubMedPubMedCentral Parsons JT, Golub SA, Rosof E, Holder C: Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial. J Acquir Immune Defic Syndr. 2007, 46 (4): 443-450. 10.1097/QAI.0b013e318158a461.CrossRefPubMedPubMedCentral
17.
go back to reference Simoni JM, Huh D, Frick PA, Pearson CR, Andrasik MP, Dunbar PJ, Hooton TM: Peer support and pager messaging to promote antiretroviral modifying therapy in Seattle: a randomized controlled trial. J Acquir Immune Defic Syndr. 2009, 52 (4): 465-473. 10.1097/QAI.0b013e3181b9300c.CrossRefPubMedPubMedCentral Simoni JM, Huh D, Frick PA, Pearson CR, Andrasik MP, Dunbar PJ, Hooton TM: Peer support and pager messaging to promote antiretroviral modifying therapy in Seattle: a randomized controlled trial. J Acquir Immune Defic Syndr. 2009, 52 (4): 465-473. 10.1097/QAI.0b013e3181b9300c.CrossRefPubMedPubMedCentral
18.
go back to reference Martin DJ, Sim JG, Sole GJ, Rymer L, Shalekoff S, van Niekerk AB, Becker P, Weilbach CN, Iwanik J, Keddy K, et al: CD4+ lymphocyte count in African patients co-infected with HIV and tuberculosis. J Acquir Immune Defic Syndr Hum Retrovirol. 1995, 8 (4): 386-391.CrossRefPubMed Martin DJ, Sim JG, Sole GJ, Rymer L, Shalekoff S, van Niekerk AB, Becker P, Weilbach CN, Iwanik J, Keddy K, et al: CD4+ lymphocyte count in African patients co-infected with HIV and tuberculosis. J Acquir Immune Defic Syndr Hum Retrovirol. 1995, 8 (4): 386-391.CrossRefPubMed
19.
go back to reference Morris L, Martin DJ, Bredell H, Nyoka SN, Sacks L, Pendle S, Page-Shipp L, Karp CL, Sterling TR, Quinn TC, Chaisson RE: Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis. 2003, 187 (12): 1967-1971. 10.1086/375346.CrossRefPubMed Morris L, Martin DJ, Bredell H, Nyoka SN, Sacks L, Pendle S, Page-Shipp L, Karp CL, Sterling TR, Quinn TC, Chaisson RE: Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis. 2003, 187 (12): 1967-1971. 10.1086/375346.CrossRefPubMed
20.
go back to reference De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, Poggio A, Pagano G, Tositti G, Cadeo G, Macor A, Toti M, D'Arminio Monforte A: Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med. 2002, 162 (18): 2125-2132. 10.1001/archinte.162.18.2125.CrossRefPubMed De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, Poggio A, Pagano G, Tositti G, Cadeo G, Macor A, Toti M, D'Arminio Monforte A: Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med. 2002, 162 (18): 2125-2132. 10.1001/archinte.162.18.2125.CrossRefPubMed
21.
go back to reference Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J: Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005, 192 (6): 992-1002. 10.1086/432762.CrossRefPubMed Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J: Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005, 192 (6): 992-1002. 10.1086/432762.CrossRefPubMed
22.
go back to reference Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM: Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol. 2007, 22 (9): 1510-1518. 10.1111/j.1440-1746.2007.05062.x.CrossRefPubMed Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM: Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol. 2007, 22 (9): 1510-1518. 10.1111/j.1440-1746.2007.05062.x.CrossRefPubMed
23.
go back to reference Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000, 356 (9244): 1800-1805. 10.1016/S0140-6736(00)03232-3.CrossRefPubMed Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000, 356 (9244): 1800-1805. 10.1016/S0140-6736(00)03232-3.CrossRefPubMed
24.
go back to reference Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL: Hepatitis C and progression of HIV disease. Jama. 2002, 288 (2): 199-206. 10.1001/jama.288.2.199.CrossRefPubMed Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL: Hepatitis C and progression of HIV disease. Jama. 2002, 288 (2): 199-206. 10.1001/jama.288.2.199.CrossRefPubMed
25.
go back to reference Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD: Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005, 19 (6): 593-601. 10.1097/01.aids.0000163936.99401.fe.CrossRefPubMed Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD: Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005, 19 (6): 593-601. 10.1097/01.aids.0000163936.99401.fe.CrossRefPubMed
26.
go back to reference Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA, Dore GJ: Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004, 18 (8): 1169-1177. 10.1097/00002030-200405210-00010.CrossRefPubMed Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA, Dore GJ: Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004, 18 (8): 1169-1177. 10.1097/00002030-200405210-00010.CrossRefPubMed
27.
go back to reference Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, Leder T, Berger A, Weidemann E, Hill A, Phillips A: Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS. 1999, 13 (8): 951-956. 10.1097/00002030-199905280-00011.CrossRefPubMed Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, Leder T, Berger A, Weidemann E, Hill A, Phillips A: Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS. 1999, 13 (8): 951-956. 10.1097/00002030-199905280-00011.CrossRefPubMed
28.
go back to reference Deeks SG, Barbour JD, Grant RM, Martin JN: Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002, 16 (2): 201-207. 10.1097/00002030-200201250-00009.CrossRefPubMed Deeks SG, Barbour JD, Grant RM, Martin JN: Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002, 16 (2): 201-207. 10.1097/00002030-200201250-00009.CrossRefPubMed
29.
go back to reference Cozzi-Lepri A, Phillips AN, Miller V, Katlama C, Ledergerber B, Vella S, Weber J, Bruun JN, Kirk O, Clotet B, Lundgrens JD: Changes in viral load in people with virological failure who remain on the same HAART regimen. Antivir Ther. 2003, 8 (2): 127-136.PubMed Cozzi-Lepri A, Phillips AN, Miller V, Katlama C, Ledergerber B, Vella S, Weber J, Bruun JN, Kirk O, Clotet B, Lundgrens JD: Changes in viral load in people with virological failure who remain on the same HAART regimen. Antivir Ther. 2003, 8 (2): 127-136.PubMed
30.
go back to reference Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, Cofrancesco J, Gallant JE, Quinn TC, Jackson B, Flexner C, Carson K, Ray S, Persaud D, Siliciano RF: Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 2005, 293 (7): 817-829. 10.1001/jama.293.7.817.CrossRefPubMed Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, Cofrancesco J, Gallant JE, Quinn TC, Jackson B, Flexner C, Carson K, Ray S, Persaud D, Siliciano RF: Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 2005, 293 (7): 817-829. 10.1001/jama.293.7.817.CrossRefPubMed
31.
go back to reference WHO: Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2009 revision. Geneva. 2010 WHO: Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2009 revision. Geneva. 2010
32.
go back to reference Oyomopito R, Lee MP, Phanuphak P, Lim PL, Ditangco R, Zhou J, Sirisanthana T, Chen YM, Pujari S, Kumarasamy N, Sungkanuparph S, Lee CK, Kamarulzaman A, Oka S, Zhang FJ, Mean CV, Merati T, Tau G, Smith J, Li PC: Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD). HIV Med. 2010, 11 (8): 519-529.PubMedPubMedCentral Oyomopito R, Lee MP, Phanuphak P, Lim PL, Ditangco R, Zhou J, Sirisanthana T, Chen YM, Pujari S, Kumarasamy N, Sungkanuparph S, Lee CK, Kamarulzaman A, Oka S, Zhang FJ, Mean CV, Merati T, Tau G, Smith J, Li PC: Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD). HIV Med. 2010, 11 (8): 519-529.PubMedPubMedCentral
Metadata
Title
Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database
Authors
Jialun Zhou
Thira Sirisanthana
Sasisopin Kiertiburanakul
Yi-Ming A Chen
Ning Han
Poh_Lian Lim
Nagalingeswaran Kumarasamy
Jun Yong Choi
Tuti Parwati Merati
Evy Yunihastuti
Shinichi Oka
Adeeba Kamarulzaman
Praphan Phanuphak
Christopher KC Lee
Patrick CK Li
Sanjay Pujari
Vanthanak Saphonn
Matthew G Law
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-361

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine